3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
152
Neoplasm Metastasis
22
Neoplasms
21
Ovarian Neoplasms
12
Sarcoma
10
Pancreatic Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
8
Melanoma
7
Endometrial Neoplasms
7
Colorectal Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Prostatic Neoplasms
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Multiple Myeloma
6
Lymphoma, Non-Hodgkin
6
Head and Neck Neoplasms
6
Carcinoma, Renal Cell
6
Recurrence
5
Medulloblastoma
5
Lung Neoplasms
5
Leukemia, Myeloid, Acute
5
Breast Diseases
5
Triple Negative Breast Neoplasms
4
Sarcoma, Ewing
4
Neoplasms by Site
4
Lymphoma, Mantle-Cell
4
Liposarcoma
4
Glioma
4
Glioblastoma
4
Colonic Neoplasms
4
Interventions
Capecitabine
6
Temozolomide
5
Octreotide
4
Leucovorin
4
Everolimus
4
Fluorouracil
3
Bevacizumab
3
vatalanib
2
pentetreotide
2
Trastuzumab
2
Sunitinib
2
Oxaliplatin
2
Magnetic Resonance Spectroscopy
2
Cisplatin
2
Bortezomib
2
Biological Therapy
2
veliparib
1
tipifarnib
1
temsirolimus
1
sapanisertib
1
romidepsin
1
regorafenib
1
pazopanib
1
palbociclib
1
motesanib diphosphate
1
lutetium Lu 177 dotatate
1
irinotecan sucrosofate
1
gallium Ga 68 dotatate
1
dehydroftorafur
1
cixutumumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Somatostatinoma
×
palbociclib
×
Clear all
NCT02806648
2018-01-23
PALBONET
Grupo Espanol de Tumores Neuroendocrinos
Phase 2
Completed
21 enrolled